ISR Immune System Regulation Holding AB starts two new programs against TBC and cancer
Based on the concept of stimulating the immune system, ISR is currently developing a second line of immune-activating chemical entities together with the Cambridge based company Isomerase. The studies in the new indications will focus on TBC and cancer. Many bacteria and tumours have developed systems that help them avoid recognition and activation of the immune system. Therefore, there is a big and increasing medical need for immune stimulatory drugs. ISR-50, our IP protected lead drug candidate has enhanced immune stimulatory properties currently explored in vitro and in animal models